FDA Advises Patients to Switch to HFA-Propelled Albuterol Inhalers

The U.S. Food and Drug Administration issued a public health advisory to alert patients, caregivers and health care professionals to switch to hydrofluoroalkane (HFA)-propelled albuterol inhalers because chlorofluorocarbon (CFC)-propelled inhalers will not be available in the United States after Dec. 31, 2008. CFC- propelled albuterol inhalers are being phased out because they are harmful to the environment by contributing to depletion of the ozone layer above the Earth’s surface. Three HFA-propelled albuterol inhalers have been approved by the FDA:
  • Proair HFA Inhalation Aerosol,
  • Proventil HFA Inhalation Aerosol, and
  • Ventolin HFA Inhalation Aerosol.
In addition, an HFA-propelled inhaler containing levalbuterol, a medicine similar to albuterol, is available as Xopenex HFA Inhalation Aerosol. Albuterol inhalers are used to treat bronchospasm (wheezing) in patients with asthma and chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. Patients use albuterol inhalers to deliver medicine directly into the lungs. The FDA is urging patients to talk with their health care professionals now about switching to HFA-propelled albuterol inhalers. These products are safe and effective replacements for CFC-propelled albuterol inhalers. HFA-propelled albuterol inhalers may taste and feel different than the CFC- propelled albuterol inhalers. The spray of an HFA-propelled albuterol inhaler may feel softer than that of a CFC-propelled albuterol inhaler. Patients must also prime and clean HFA-propelled albuterol inhalers. Doing so prevents buildup of the drug in the inhalation device, and buildup can block the medicine from reaching the lungs. Each HFA-propelled albuterol inhaler has different priming, cleaning, and drying instructions, and patients should read and understand the instructions first before using the inhaler. For more information: http://www.fda.gov/cder/mdi/albuterol.htm
http://www.fda.gov/bbs/topics/NEWS/2008/NEW01842.html